U.S. markets open in 7 hours 24 minutes

Can-Fite BioPharma Ltd. (CANF)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.2700-0.0200 (-0.87%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.2900
Open2.2600
Bid0.0000 x 1100
Ask0.0000 x 1300
Day's Range2.2450 - 2.3300
52 Week Range1.5100 - 4.3900
Volume187,819
Avg. Volume4,222,726
Market Cap39.288M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-1.2000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show
    Benzinga

    Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show

    Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead drug candidate Namodenoson is expected to enter the Phase 3 study in Q4 2021. The studies showed that CBD-rich T3/C15 cannabis fraction inhibited the growth of liver HEP-3b hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways. The Wnt signaling pathway is known to be highly active in controlling the growth of liver cancer cells. The company has filed patent applications for cannabinoid-based therapies where the A3AR target is overexpressed, including liver cancer. Price Action: CANF shares are down 1.7% at $2.41 in the market session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaSorrento Therapeutics To Buy ACEA Therapeutics For M In StockElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
    Business Wire

    Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

    Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

  • Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
    Business Wire

    Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the six existing distribution agreements it has signed for its advanced stage drug candidates Piclidenoson and Namodenoson in select territories have remaining potential milestone payments of up to approximately $130 million plus double digit royalties on net sales following regulatory approval. In addition, to date, the Company has collected over $20 million in non-dilutive upfront and milestone payments.